Sphere Fluidics introduced the Cyto-Cellect™ Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System for rapid and cost-effective measurement of antibody class and productivity in cell line development.
- First in a new range to advance identification and selection of cells with the highest productivity
- Assay-ready reagent kit to reduce timelines and enhance efficiency in cell line development
Cambridge, UK, 9 September 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced the Cyto-Cellect™ Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System for rapid and cost-effective measurement of antibody class and productivity in cell line development.
The Cyto-Cellect Human IgGK Detection Kit has been developed to provide Cyto-Mine users with an easy-to-use, standardized assay format for the detection of secreted human antibodies in picodroplets. The sensitive FRET-based assay rapidly detects the presence of human IgG with kappa light chain after secretion from encapsulated cells, to characterize and measure antibody production. Rapid detection of IgG enables high-throughput identification and selection of cells with the highest productivity for more efficient cell line development.
With optimized ratios of Sphere Fluidics’ Human IgGK Detection probes, the Cyto-Cellect Human IgGK Detection Kit offers a sensitive and robust assay ideal for streamlining cell isolation and titer determination. The complete kit has been manufactured without the use of animal-derived materials, offering an animal-origin-free reagent kit that provides confidence in the reproducibility and consistency of the assay and conforms to regulatory requirements in cell line development.
Dr Zoe Nilsson, Global Product Marketing Manager, Sphere Fluidics, said: “Our expert team has applied extensive knowledge of assay requirements to develop the Cyto-Cellect Human IgGK Detection Kit, offering users a sensitive, yet robust assay solution for the Cyto-Mine platform. The addition of this assay-ready kit to Sphere Fluidics’ product portfolio provides a rapid, yet cost-effective solution to further support and reduce cell line development timelines.”
The Cyto-Mine platform will be on display in Boston, MA at BioProcess International from 9–12 September 2019 (Stand #1306).
For more information about Sphere Fluidics’ Cyto-Cellect Human IgGK Detection Kit, please visit: https://spherefluidics.com/
ENDS
Notes to Editors
For further information please contact:
Sphere Fluidics
Dr Zoe Nilsson
Tel: +44 (0)1223 6288892
Email: zoe.nilsson@spherefluidics.com
Zyme Communications
Dr Michelle Ricketts
Tel: +44 (0)7789 053885
Email: michelle.ricketts@
About Sphere Fluidics www.spherefluidics.com
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems for biologics discovery and cell line development.
Sphere Fluidics’ Cyto-Mine® System integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine® is underpinned by the Company’s patented, microfluidic picodroplet technology.
Sphere Fluidics is located in Granta Park, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company has also internationalized its business via a global network of distributors.
Follow Sphere Fluidics on Twitter @SphereFluidics and LinkedIn @Sphere Fluidics Limited.
